Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Neoplasms 5Anemia 5Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia 1Fatigue 1Critical Illness 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × Darbepoetin alfa × Clear all
NCT00858364 2022-11-30

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Amgen

Phase 3 Terminated
2,549 enrolled 19 charts
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Pleural Effusion, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡